CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia

This study tests a CAR-T cell therapy that targets the CD19 protein for adults with acute lymphoblastic leukemia (ALL), a blood cancer, that has come back or is no longer responding to chemotherapy. **You may be eligible if...** - You are 18–75 years old - You have B-cell ALL that has relapsed at least twice, or did not respond to two rounds of standard chemotherapy - Your leukemia is Philadelphia chromosome-positive and you have failed or cannot tolerate two tyrosine kinase inhibitor drugs - You have relapsed after a stem cell transplant - You cannot have or don't have a suitable donor for a stem cell transplant - At least 5% of your bone marrow contains leukemia cells - Your cancer cells still express CD19 **You may NOT be eligible if...** - Your leukemia no longer expresses CD19 - You have had severe reactions (grade 3 or higher) to previous CAR-T therapy - You have active brain or spinal cord involvement by leukemia (unless you are in remission for that) - You are pregnant or breastfeeding - Your organ function is inadequate for the therapy Talk to your doctor to see if this trial is right for you.